Investor Presentation

41 Investor presentation First six months of 2022 Novo Nordisk has a leadership position within the growing diabetes market Novo NordiskⓇ Global diabetes market by treatment class¹ Novo Nordisk remains global diabetes value Novo Nordisk market share and share of market leader growth DKK billion 35% Market CAGR: 4% 350 60% 31% 30% 300 CAGR: -3% 25% 250 40% CAGR: 16% 20% 200 15% 39% 31% 25% 150 CAGR: -4% 20% 10% 100 19% 50 5% CAGR: 19% 0 0% 0% 2017 2018 2019 2020 2021 May May May 2012 2022 2019 May 2022 GLP-1 Insulin SGLT-2i DPP-4i Novo Nordisk -Sanofi -Merck -Astra Zeneca -J&J -Takeda -Eli Lilly BI -Novartis -NN market share -NN share of growth -Market growth (right axis) -NN growth (right axis) 1 Data is based on company reported sales from Sanofi, Eli Lilly, AstraZeneca, GSK, Novartis, Johnson & Johnson, and Merck. Data does not include generic metformin, sulphonylureas or thiazolidinedione BI: Boehringer Ingelheim; J&J: Johnson & Johnson Source: IQVIA MAT, May 2022 value figures Note: IQVIA data can be inflated due to use of list prices in the US

View entire presentation